Penn National Gaming Inc. (NASDAQ:PENN) shares fell -5.51% in last trading session and ended the day at $16.11. PENN Gross Margin is 43.30% and its has a return on assets of -9.30%. Penn National Gaming Inc. (NASDAQ:PENN) quarterly performance is -13.76%.
On November 11, 2015, Penn National Gaming, Inc. (NASDAQ:PENN) received a notification from the Nasdaq Stock Market (“Nasdaq”) as a result of the Company’s failure to file the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (the “Filing”) as required under Nasdaq’s Listing Rule 5250(c)(1). In accordance with Nasdaq listing requirements, the Company has at least 60 calendar days to submit a plan to regain compliance. The Company expects to make the Filing by year-end, thereby immediately regaining compliance.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) ended the last trading day at $6.58. Company weekly volatility is calculated as 6.16% and price to cash ratio as 5.08. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) showed a weekly performance of -12.85%.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced appointment of Patrick Fabbio as Chief Financial Officer. Mr. Fabbio, the former Vice President, Global Corporate Finance at NPS Pharmaceuticals, Inc., has over 20 years of financial experience in the healthcare sector at both publicly-traded and privately-held companies.
On 16 November, TG Therapeutics, Inc. (NASDAQ:TGTX) shares increased 0.46% and was closed at $13.01. TGTX EPS growth in last 5 year was 57.00%. TG Therapeutics, Inc. (NASDAQ:TGTX) year to date (YTD) performance is -17.87%.
On 9 November, TG Therapeutics, Inc. (NASDAQ:TGTX) reported consolidated net loss for the third quarter ended September 30, 2015, excluding non-cash items, was approximately $12.4 million, which included approximately $6.9 million of manufacturing and CMC expenses in preparation for Phase 3 clinical trials and potential commercialization. The consolidated net loss for the third quarter ended September 30, 2015, inclusive of non-cash items, was $13.7 million, or $0.28 per diluted share, compared to a consolidated net loss of $17.5 during the comparable quarter in 2014, representing a decrease in consolidated net loss of $3.8 million.
China New Borun Corporation (NYSE:BORN) shares fell -5.15% in last trading session and ended the day at $1.29. BORN Gross Margin is 10.30% and its has a return on assets of 2.30%. China New Borun Corporation (NYSE:BORN) quarterly performance is 12.17%.
On 11 November, China New Borun Corporation (NYSE:BORN) reported Total revenue increased 25.0% to RMB661.4 million ($104.0 million[1]) from RMB529.2 million in the third quarter of 2014. Gross profit increased 45.7% to RMB66.3 million ($10.4 million) from RMB45.5 million in the third quarter of 2014.
Bio-Techne Corp. (NASDAQ:TECH) caters to the Healthcare space. It has a net profit margin of 23.30% and weekly performance is -0.88%. On the last day of trading company shares ended up at $87.70. Bio-Techne Corp. (NASDAQ:TECH) distance from 50-day simple moving average (SMA50) is 4.07%.
Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2015. The quarterly dividend will be payable November 27, 2015 to all common shareholders of record on November 13, 2015. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Leave a Reply